Free tool
Drug Trial Radar: Oncology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
559
Active, not recruiting, industry sponsors, Oncology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting600
- Completed2,063
559 trials
Showing 1 to 25, recently updated first.
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerPivotal-lookingActive, not recruiting
Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
NCT05253651 · 325 participants · Start Oct 24, 2022 · Primary completion Dec 31, 2027
Drug: tucatinib; trastuzumab and 6 more · For: Colorectal Neoplasms
Sites: Glendale, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 319 sites in all
- Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)Pivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT02319837 · 1,068 participants · Start Dec 17, 2014 · Primary completion Jan 31, 2023
Drug: Enzalutamide; Placebo (No longer applicable in Open Label study period) and 1 more · For: Hormone Sensitive Prostate Cancer; Prostate Cancer; Cancer of the Prostate
Sites: Birmingham, Alabama; Anchorage, Alaska; Tucson, Arizona · 255 sites in all
- A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04195750 · 755 participants · Start Feb 27, 2020 · Primary completion Apr 15, 2024
Drug: Belzutifan; Everolimus · For: Carcinoma, Renal Cell
Sites: Birmingham, Alabama; La Jolla, California; Santa Rosa, California · 172 sites in all
- Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsPivotal-lookingActive, not recruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT05215340 · 740 participants · Start Mar 4, 2022 · Primary completion Mar 4, 2030
Drug: Datopotamab Deruxtecan; Pembrolizumab · For: Metastatic Non Small Cell Lung Cancer
Sites: Chandler, Arizona; Los Angeles, California; Santa Barbara, California · 234 sites in all
- A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung CancerPivotal-lookingActive, not recruiting
CelltrionIndustry
NCT06939595 · 225 participants · Start Jan 30, 2025 · Primary completion Feb 2027
Drug: CT-P51; EU-approved Keytruda · For: Non Squamous Non Small Cell Lung Cancer
Sites: Tbilisi, Georgia
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersPivotal-lookingActive, not recruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT05152147 · 920 participants · Start Dec 2, 2021 · Primary completion Jul 15, 2026
Drug: Zanidatamab; Tislelizumab and 5 more · For: Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Pergamino, Argentina · 227 sites in all
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseasePivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT06760637 · 1,037 participants · Start Jan 6, 2025 · Primary completion Jan 2, 2029
Drug: PF-07220060; letrozole and 3 more · For: Breast Cancer
Sites: Birmingham, Alabama; Chandler, Arizona; Gilbert, Arizona · 460 sites in all
- A Study of Sasanlimab in People With Non-muscle Invasive Bladder CancerPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT04165317 · 1,068 participants · Start Dec 30, 2019 · Primary completion Dec 2, 2024
Drug: PF-06801591; Bacillus Calmette-Guerin · For: Non-muscle Invasive Bladder Cancer
Sites: Tucson, Arizona; Little Rock, Arkansas; La Jolla, California · 195 sites in all
- A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin LymphomaPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06230224 · 216 participants · Start Feb 15, 2024 · Primary completion May 29, 2028
Drug: Odronextamab; Ifosfamide and 7 more · For: B-Cell Non-Hodgkin Lymphoma (B-NHL)
Sites: Ciudad Autonoma de Buenos Aires, Argentina; La Plata, Argentina; San Juan Bautista, Argentina · 81 sites in all
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)Pivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06140836 · 190 participants (planned) · Start Dec 21, 2023 · Primary completion Feb 16, 2027
Drug: Repotrectinib; Crizotinib · For: Carcinoma, Non-Small-Cell Lung
Sites: Boston, Massachusetts; Mineola, New York; New York, New York · 120 sites in all
- A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT05654623 · 624 participants · Start Mar 3, 2023 · Primary completion Jan 31, 2025
Drug: ARV-471; Fulvestrant · For: Advanced Breast Cancer
Sites: Encinitas, California; Fountain Valley, California; Fresno, California · 312 sites in all
- A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.Pivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT06629779 · 900 participants (planned) · Start Oct 22, 2024 · Primary completion Sep 30, 2027
Drug: PF-06821497; Placebo and 1 more · For: Metastatic Castration-Resistant Prostate Cancer
Sites: Chandler, Arizona; Gilbert, Arizona; Glendale, Arizona · 203 sites in all
- A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06077760 · 868 participants (planned) · Start Dec 6, 2023 · Primary completion Jun 25, 2030
Drug: Intismeran autogene; Pembrolizumab · For: Non-small Cell Lung Cancer
Sites: Anchorage, Alaska; Tucson, Arizona; Yuma, Arizona · 229 sites in all
- Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionPivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT07214779 · 13 participants · Start Dec 9, 2025 · Primary completion Oct 12, 2027
Drug: INCB123667; Investigator's choice of chemotherapy · For: Ovarian Cancer
Sites: Anchorage, Alaska; Tucson, Arizona; Duarte, California · 198 sites in all
- A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)Pivotal-lookingActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06838273 · 724 participants · Start Feb 24, 2025 · Primary completion Dec 2028
Drug: BL-B01D1; Osimertinib and 1 more · For: Non-small Cell Lung Cancer
Sites: Shanghai, China
- A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate CancerPivotal-lookingActive, not recruiting
Aragon Pharmaceuticals, Inc.Industry
NCT01946204 · 1,207 participants · Start Oct 14, 2013 · Primary completion May 19, 2017
Drug: Apalutamide; Placebo · For: Prostatic Neoplasms
Sites: Birmingham, Alabama; Anchorage, Alaska; Chandler, Arizona · 379 sites in all
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponsePivotal-lookingActive, not recruiting
MoonLake Immunotherapeutics AGIndustry
NCT06641089 · 600 participants (planned) · Start Oct 15, 2024 · Primary completion Jan 4, 2027
Drug: Sonelokimab; Placebo and 1 more · For: Arthritis, Psoriatic
Sites: Avondale, Arizona; Chandler, Arizona; Flagstaff, Arizona · 143 sites in all
- A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular LymphomaPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06097364 · 733 participants (planned) · Start Nov 14, 2023 · Primary completion Jul 29, 2029
Drug: Odronextamab; Rituximab and 4 more · For: Follicular Lymphoma (FL)
Sites: Plantation, Florida; Noblesville, Indiana; Wichita, Kansas · 145 sites in all
- A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05057494 · 607 participants · Start Sep 12, 2022 · Primary completion Jul 15, 2027
Drug: Acalabrutinib; Venetoclax and 1 more · For: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sites: Tucson, Arizona; La Jolla, California; Longmont, Colorado · 37 sites in all
- Phase IIIb Study of Ribociclib + ET in Early Breast CancerPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05827081 · 1,466 participants · Start Feb 28, 2024 · Primary completion Sep 7, 2029
Drug: Ribociclib; Letrozole and 4 more · For: Early Breast Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Goodyear, Arizona · 214 sites in all
- Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT04246047 · 494 participants · Start May 7, 2020 · Primary completion Oct 2, 2023
Drug: Belantamab mafodotin; Daratumumab and 2 more · For: Multiple Myeloma
Sites: Yuma, Arizona; Mission, Kansas; Denver, North Carolina · 143 sites in all
- A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04739761 · 506 participants · Start Jun 22, 2021 · Primary completion Feb 8, 2024
Drug: Trastuzumab Deruxtecan · For: Breast Cancer
Sites: Boston, Massachusetts; Durham, North Carolina; Adelaide, Australia · 81 sites in all
- A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04546009 · 992 participants · Start Oct 9, 2020 · Primary completion Jan 30, 2026
Drug: Giredestrant; Giredestrant-matched Placebo and 4 more · For: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Sites: Fountain Valley, California; Long Beach, California; San Leandro, California · 256 sites in all
- Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT02962414 · 206 participants · Start Aug 23, 2017 · Primary completion Feb 26, 2027
Drug: everolimus · For: Tuberous Sclerosis Complex
Sites: Phoenix, Arizona; Los Angeles, California; Oakland, California · 68 sites in all
- Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform NeurofibromasPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04924608 · 145 participants · Start Nov 19, 2021 · Primary completion Aug 5, 2024
Drug: Selumetinib · For: Neurofibromatosis 1; Plexiform Neurofibroma (PN)
Sites: Gainesville, Florida; Rockville, Maryland; St Louis, Missouri · 34 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.